Adizie JB, Khakwani A, Beckett P, Navani N, West D, Woolhouse I, Harden SV (2019) Stage III non-small cell lung cancer management in England. Clin Oncol 31:688–696

Article  CAS  Google Scholar 

Afzal MZ, Dragnev K, Shirai K (2018) A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. J Thorac Dis 10:3575–3584

Article  PubMed  PubMed Central  Google Scholar 

Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Ramos MY, Mota-Vega B, Carmona A, Álvarez MPP (2020) Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol 6:856–864

Article  PubMed  Google Scholar 

Barbara B, Harrington KJ, Greil R, Soulières D, Tahara M, Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–28

Article  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373:1627–1639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro J, Carpeno AP, Arrieta O, Frontera OA, Chiari R (2021) Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer. J Clin Oncol 39:723–733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bratman SV, Cindy Yang SY, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer 1:873–881

Article  CAS  PubMed  Google Scholar 

Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461–471

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong Z-Y, Zhong W-Z, Zhang X-C, Jian Su, Xie Z, Liu S-Y, Hai-Yan Tu, Chen H-J, Sun Y-L, Zhou Q (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23:3012–3024

Article  CAS  PubMed  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M (2021) NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw 19:254–266

Article  CAS  PubMed  Google Scholar 

Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 17:725–741

Article  PubMed  Google Scholar 

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C (2018) Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 24:1441–1448

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378:2078–2092

Article  CAS  PubMed  Google Scholar 

Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J (2020) Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol 15:816–826

Article  CAS  PubMed  Google Scholar 

Huang Di, Cui P, Huang Z, Zhaozhen Wu, Tao H, Zhang S, Xiang R, Yi Hu (2021) Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. J Cancer Res Clin Oncol 147:881–891

Article  CAS  PubMed  Google Scholar 

Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M (2017) Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Sci 108:1974–1984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)00797-2

Article  PubMed  PubMed Central  Google Scholar 

Landre T, Justeau G, Assié J-B, Chouahnia K, Taleb C, Chouaid C, Duchemann B (2021) Anti PD-(L) 1 in KRAS mutant advanced nsclcs: a meta-analysis of randomized controlled trials. Wolters Kluwer Health

Google Scholar 

Li N, Wang Z, Xu N, Ying K, Liu Y, Lu S, Yang J (2018) Evaluation of efficacy and safety of Sindilizumab in patients with advanced non-small cell lung cancer in China (in Chinese). In: Abstracts of the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Xiamen, China, p 15

Liu S-Y, Sun H, Zhou J-Y, Jie G-L, Xie Z, Shao Y, Zhang X, Ye J-Y, Chen C-X, Zhang X-C (2020) Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark Res 8:1–7

Article  Google Scholar 

Mao S, Zhou F, Liu Y, Yang S, Chen B, Xu J, Wu F, Li X, Zhao C, Wang W (2021) ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunol Immunother 71(1):219–28

Article  PubMed  Google Scholar 

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15:1657–1669

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:1823–1833

Article  CAS  PubMed  Google Scholar 

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

Article  PubMed  Google Scholar 

Shi Y, Hang Su, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6:e12–e19

Article  PubMed  Google Scholar 

Shukla N, Althouse SK, Perkins S, Furqan M, Leal T, Hanna NH, Durm GA (2021) A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: big ten cancer research consortium BTCRC-LUN15–029. Wolters Kluwer Health

Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33

Article  PubMed  Google Scholar 

Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA (2021) IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2021.07.009

Article  PubMed  Google Scholar 

Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713–6721

Article  CAS  PubMed  Google Scholar 

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong SuFey (2019) Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med 25:920–928

Article  CAS  PubMed  Google Scholar 

Wanderley CW, Colon DF, João PM, Luiz FF, Oliveira PR, Viacava CA, Leite JA, Pereira CM, Silva CR, Silva, and Rangel L. Silva. (2018) Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Can Res 78:5891–5900

Article  CAS  Google Scholar 

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF (2016) Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 8:33452–3452

Article  Google Scholar 

Wu Y-L, Shun Lu, Cheng Y, Zhou C, Wang J, Mok T, Zhang Li, Hai-Yan Tu, Lin Wu, Feng J (2019) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 14:867–875

Article  CAS  PubMed  Google Scholar 

Zhai X, Jing X, Li J, Tian Y, Xu S, Wang M, Zhu H (2020) Clinical outcomes for PD-1 inhibitor plus chemotherapy as second-line or later therapy compared to PD-1/PD-L1 inhibitor alone in advanced non-small-cell lung cancer. Front Oncol. https://doi.org/10.3389/fonc.2020.556275

Article  PubMed  PubMed Central  Google Scholar